書誌事項
- タイトル別名
-
- Clinical Efficacy of Once Daily 500mg Levofloxacin Administration in Treating Adult Acute Pharyngotonsillitis
- 薬物 成人急性咽頭・扁桃炎に対するLevofloxacin 500mg1日1回投与の有用性に関する検討
- ヤクブツ セイジン キュウセイ イントウ ヘントウエン ニ タイスル Levofloxacin 500mg1ニチ 1カイ トウヨ ノ ユウヨウセイ ニ カンスル ケントウ
この論文をさがす
抄録
In pharmacokinetic and clinical studies of once daily 500 mg levofloxacin (LVFX) in adults with acute pharyngotonsillitis, we assessed disease severity and LVFX efficacy using scoring based on local findings and clinical symptoms.<br> The LVFX tissue concentration of 2.58 to 4.12 hours after single 500 mg administration was 7.791±1.686 μg/g (mean±SD) in the palatine tonsil, with a tissue/plasma concentration ratio of 1.66±0.20. The clinical efficacy (test of cure) was 95.0% (19/20). Bacteriological eradication was 100% (7/7). Adverse reactions, all mild to moderate, occurred in 28.6% (6/21). Side effects, but no serious or clinically significant event, occurred in 4.8% (1/21).<br> In conclusion, LVFX once daily 500 mg p.o. entered well into palatine tonsil tissue and appears useful in treating acute pharyngotonsillitis. Data confirmed that scoring was very useful in deciding appropriate acute pharyngotonsillitis treatment.<br>
収録刊行物
-
- 耳鼻咽喉科臨床
-
耳鼻咽喉科臨床 104 (9), 657-666, 2011
耳鼻咽喉科臨床学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679239915264
-
- NII論文ID
- 10029495375
-
- NII書誌ID
- AN00107089
-
- ISSN
- 18844545
- 00326313
-
- NDL書誌ID
- 11225254
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可